XFTB yields 1000000.00% · ABBV yields 3.06%● Live data
📍 XFTB pulled ahead of the other in Year 1
Combined, XFTB + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XFTB + ABBV for your $10,000?
XFit Brands, Inc. designs, develops, markets, and sells functional equipment, training gears, and apparel and accessories for the impact sports market and fitness industry worldwide. It offers functional fitness stations, including XTC, CTC, and UTC training equipment, as well as mobile fitness training stations used in set up for mobile events, such as mobile boot camps, community events, trade shows, and outdoor competitions. The company also provides training and protective gears comprising mixed martial arts and boxing gloves, punching mitts, thai pads, body shields, and heavy bags; cages and rings to ultimate fighting championship gyms; and bag rack systems. In addition, it offers apparel; functional training equipment and accessories consisting of weight plates, kettle bells, resistance bands, weight bars and dumbbells, jump ropes, slam balls, and plyometrix boxes used in cross training and other related fitness regimens; and fitness training programs. The company provides its products under the Throwdown, XFit Brands, and Transformations brand names. XFit Brands, Inc. markets and sells its products through various channels, including gyms, fitness facilities, third party catalogues, independent distributors, and licensees, as well as directly to consumers through its Website. The company was founded in 2003 and is based in Lake Forest, California.
Full XFTB Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.